|
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Clinical research trials and A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.. A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. clinical trial. Human subjects often get the best healthcare possible for their A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.  A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
For Condition: Sarcoma, Kaposi,HIV Infections
Status: Completed
Sponsor(s): Nexstar Pharmaceuticals ,
Synopsis: To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy. To compare the duration of responses, response rates, and times to response.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV infection. - Advanced Kaposi's sarcoma. Prior Medication: Allowed: - Prior intralesional vinblastine. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Acute intercurrent infection other than genital herpes. - Uncompensated cardiovascular, hepatic, renal, or pulmonary disease unrelated to Kaposi's sarcoma. - Symptomatic peripheral neuropathy. - Any condition that compromises ability to give informed consent or complete the study. Concurrent Medication: Excluded: - Concurrent ganciclovir. Patients with the following prior conditions are excluded: - Symptomatic AIDS-defining opportunistic infection within 2 weeks of entry. - History of malignancy other than Kaposi's sarcoma, basal cell carcinoma, or carcinoma in situ of the cervix. Prior Medication: Excluded: - Prior systemic chemotherapy. - Intralesional therapies within 7 days prior to study entry. - Growth factors (G-CSF or GM-CSF), immune modifiers, or investigational agents within 14 days prior to study entry. - Interferon preparations (alpha or beta) within 28 days prior to study entry. Prior Treatment: Excluded within 7 days prior to study entry: - Radiation. - Local therapies (e.g., cryotherapy).
Total Enrollment:
Location and Contact Information:
Kenneth Norris Jr Cancer Hosp
Los Angeles, California, 90033
United States
Univ of Arizona / Arizona Cancer Ctr
Tucson, Arizona, 85724
United States
Davies Med Ctr
San Francisco, California, 94114
United States
Saint Francis Mem Hosp
San Francisco, California, 94109
United States
Desert Hosp Comprehensive Cancer Ctr
Palm Springs, California, 92262
United States
Northwestern Univ Med School
Chicago, Illinois, 60611
United States
New York Univ Med Ctr
New York City, New York, 10016
United States
Univ of Miami Dept of Medicine
Miami, Florida, 33136
United States
Denver Gen Hosp
Denver, Colorado, 802044507
United States
George Washington Univ Med Ctr
Washington D.C., District of Columbia, 20037
United States
New England Deaconess Hosp
Boston, Massachusetts, 02215
United States
Kaiser Permanente Med Ctr
Portland, Oregon, 97227
United States
Dr Edward Stool
Houston, Texas, 77004
United States
Additional Information:
Study ID Numbers: 121A; 103-09
Study Start Date:
Record last reviewed: March 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002093
Other Hiv Infections Studies:
1. Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
2. Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
3. A Study of Patients with AIDS Syndrome
4. A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
5. A Phase I Trial of Tecogalan sodium (DS-4152) Administered as an Infusion Every 21 Days
Related Studies:
Other HIV Infections Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
|
|
|
|
|
|
|
|
